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Abstract
Introduction: Considering the increasing number of patients referred to gastroenterology clinics, we report a suspected case of
coronavirus disease 2019 (COVID-19) with only gastrointestinal (GI) presentation in Qom, Iran.
Case Presentation: A 74-year-old man with epigastric pain, diarrhea and vomiting for one week was treated, based on the routine
abdominal treatment protocol. Since all GI symptoms were resistant to therapy, we decided to perform laboratory assays for a more
accurate diagnosis of the disease. Considering the persistence of abdominal pain and nausea, abdominal and pelvic computed
tomography (CT) scans, as well as endoscopy and colonoscopy, were performed. After performing the chest CT scan, we noticed the
involvement of the lungs. The patient did not have any respiratory symptoms, and at the time of his hospitalization, the COVID-19
epidemic had been reported in Iran. With the progression of the disease, he started to experience mild fever (38°C). Using a specific
COVID-19 kit, he was diagnosed with COVID-19 after precise evaluations. However, without any medications, all of his symptoms
subsided after 2 - 3 weeks.
Conclusions: It is important for all physicians to know that some pure GI symptoms, which are resistant to therapy, may be the only
symptoms in suspected COVID-19 patients. Timely diagnosis and isolation of these patients can guarantee population to avoid the
spread of this highly contagious infection.
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1. Introduction
The global spread of the coronavirus disease 2019
(COVID-19), as a highly infectious disease, have been af-
fected thousands people in all of the world (1, 2). This infec-
tion has led to the death of more people than severe acute
respiratory syndrome (SARS) and the Middle East respira-
tory syndrome (MERS), although it has a lower fatality rate.
In Iran, the ongoing COVID-19 epidemic was first reported
in Qom. It is important to note that due to the COVID-19
epidemic in Iran, the number of patients, referred to our
gastroenterology clinics in Shahid Beheshti Hospital, had
increased by 20% (3). After the first report of this infection
in Iran, all clinical evaluations, as well as treatment and
clinical outcomes of patients with laboratory-confirmed
COVID-19, were recorded.
Considering the increasing number of patients re-
ferred to gastroenterology clinics and reports of some
therapy-resistant pure gastrointestinal (GI) symptoms, we
suspected a case of COVID-19 in one of our patients. It
should be mentioned that we encounter a large number
of patients with only GI symptoms, whereas in this case
report, we only documented one case, referred to our gas-
troenterology clinic. Some important questions need to be
addressed promptly to determine whether pure GI symp-
toms appear without the incidence of respiratory disorder
in confirmed COVID-19 patients. The answer to these ques-
tions may lead to the effective management of the disease
before affecting and transferring of SARS-CoV-2 to heath
people who were in close contact with infected patients
with pure GI symptoms. With this background in mind,
we aimed to collect and analyze the detailed clinical fea-
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tures and chest computed tomography (CT) scans of an old
male patient with an only GI disorder without respiratory
involvement.
2. Case Presentation
A 74-year-old man was referred to our gastroenterology
clinic with complaints of abdominal pain, diarrhea, vom-
iting, and chest pain for two weeks. He did not report any
coughing, dyspnea, or respiratory disorders. His medical
history indicated diabetic hypertension. He also avoided
smoking and drinking.
Upon admission to the hospital, he looked ill, and his
vital signs were as follows: blood pressure: 110/60 mmHg;
pulse rate: 79 bpm; respiratory rate: 16 bpm; and oral tem-
perature: 38°C. The patient had a medical history of di-
abetes and hypertension. After one week of hospitaliza-
tion, he presented with fever and sweating. For a better
examination, laboratory tests were performed; the results
are summarized in Table 1. The CBC test revealed the in-
creased level of WBC and the decreased level of RBC. The
serum levels of alkaline phosphatase and amylase were in
the normal range. Also, endoscopy and colonoscopy did
not indicate any abnormalities. With regard to the increas-
ing prevalence of laboratory-confirmed COVID pneumo-
nia (based on conventional PCR assay and sequencing of
PCR amplicons using a throat swab) and dyspnea, in addi-
tion to the results of physical examinations and laboratory
tests, we performed a chest CT scan due to its high diagnos-
tic value, high accuracy (low false-negative rate), and time
efficiency (4). The chest CT scan revealed small bilateral
peripheral consolidations with ground-glass opacity and a
crazy paving pattern (Figure 1).
3. Discussion
In this case report, we described the clinical findings
of an old male patient with a GI disorder, who was sus-
pected of COVID-19. After administering medications for
one week, he still showed resistance to therapy. We sus-
pected COVID-19, as the onset of outbreak was reported in
Iran at the time. For further evaluations, a biochemical as-
say was carried out; however, it failed to provide more data
for a precise diagnosis. Due to the persistence of abdomi-
nal pain, as well as nausea resistant to therapy, pelvic and
abdominal CT scans, endoscopy, and colonoscopy were
performed; nevertheless, the results were in the normal
range. The chest CT scan revealed pleural constipation and
sub-pleural constipation on the left side of the diaphragm.
The patient was isolated in a negative pressure room for
two weeks, and without any medications, all of his symp-
toms subsided (5).
Based on the present results, we should be aware of
the possibility of COVID-19 and the progression of pneumo-
nia in patients following the emergence of pure GI symp-
toms; such awareness may be important in the progno-
sis of COVID-19 pneumonia (6). Recently, Zou et al. (7), re-
ported that angiotensin-converting enzyme 2 (ACE2) is the
main associate receptor of SARS-CoV-2 and the spike (S) pro-
tein of 2019-nCoV had a high affinity to ACE-2, which medi-
ate the virus entrance to the target cell, causing the final in-
fection. It has been demonstrated that ACE2 receptors can
be expressed in the oral cavity and are abundantly found in
epithelial cells. The overexpression of ACE2 receptors has
also been indicated in the colon, intestines, and gallblad-
der. Therefore, with notice to this point that the viral mu-
tations may occur during transmission, associated clinical
features of SARS-CoV-2 during its spread is welcome.
According to the epidemiological findings reported by
Lai et al. (8), fever was the most common symptom among
adult patients (92.8%; n = 258), followed by cough (69.8%;
n = 194), dyspnea (34.5%; n = 96), myalgia (27.7%; n = 77),
headache (7.2%; n = 20), and diarrhea (6.1%; n = 17) (3, 8).
Nevertheless, our observations were only related to a sin-
gle case, whereas a larger number of patients suspected
of COVID-19 are referred to our gastroenterology clinics.
Therefore, we need more time to evaluate new confirmed
cases of COVID-19. Precise recording of all GI symptoms and
interpretation of the findings should also be addressed in
new patients. Recording all clinical symptoms, as well as,
GI follow-up studies in patients with the COVID-19, is not
without merit and can be a great help in timely diagnosis
and treatment of the disease.
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Table 1. The Results of the Laboratory Examination of 74-Year-Old Man with COVID-19
Test, Unit Result Reference Range
Blood Biochemistry
FBS, mg/dL 109 70 - 99; diabetic: > 126
Creatinine, mg/dL 1.54a 0.7 - 1.4
Cholesterol, mg/dL 105 < 200
Triglycerides, mg/dL 100 < 150
HDL, mg/dL 36 Low risk: > 60
Total bilirobin, mg/dL 1.37a 0.1 - 1.2
Direct bilirobin, mg/dL 0.36a 0 - 0.3
Indirect bilirobine, mg/dL 1.01 0 - 1.1
SGOT (AST), U/L 30 11 - 37
SGPT (ALT), U/L 28 13 - 40
Alkaline phosphatase, U/L 139 100 - 460
Amylase serum, U/L 82 0 - 100
Iron (Fe), µg/dL 89 40 - 120
TIBC, µg/dL 419 230 - 440
Hb A1c, % 6.2 Non diabetic: 4 - 6; diabetic: > 6.5
Estimated average glucose, mg/dL 131 This test is a calculated glucose over the past 2 - 3 months period based on Hb
A1c results
Serology, Endocrinology and Tumor Marker
CRP, mg/L 4.4 Up to 6
Ferritin, ng/mL 95.8 20 - 250
Total PSA, ng/mL 0.3 0 - 4
AFP (Clia), IU/m 3.22 0 - 4
CEA (Clia), IU/mL 2.02 Up to 4.7
Keton Negative -
Hematology
WBC, ×103 10.70a 4.1 - 10.5
Neutrophil, % 53.30 43 - 78
Lymphocyte, % 33.70 15 - 45
Monocyte, % 9.70 4 - 9
Eosinophil, % 3.00 1 - 7
Basophil, % 0.30 0.3 - 1.3
Immature granulocyte, % 0.20 0.16 - 0.62
Neutrophil, ×103 5.70 2 - 7.7
Lymphocyte, ×103 3.61 1 - 2.7
Monocyte, ×103 1.04 0.3 - 0.7
Eosinophil, ×103 0.32 0.2 - 0.6
Basophil, ×103 0.03 0.01 - 0.3
RBC, 106 /µL 4.31 4.5 - 5.9
Hb, g/dL 13.80 13.5 - 17.5
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HTC, % 39.90 37 - 53
MCV, fL 92.6 80 - 100
MCH, pg 32.00 26 - 34
MCHC, g/dL 34.60 32 - 36
RDW-CV, % 13.80 11.5 - 16
RDW-SD, fL 47.10 38 - 50
Platelet, 103 /µL 209.00 150 - 450
PDW, fL 13.00 9.5 - 15.2
MPV, fL 10.90 9.4 - 12.3
P-LCR, % 32.70 19.4 - 43.7
PCT, % 0.23 0.19 - 0.39
ESR 1 h, mm/h 21a 0 - 20
Urine Analysis
Color Light yellow -
Appearance Clear -










RBC/hpf 0 - 1 -
WBC/hpf 1 - 2 -





Abbreviations: AFP, alpha-fetoprotein; ALT, alanine transferase; AST, aspartate amino transferase; CEA, embryonic carcinoma antigen; CRP, C-reactive protein; FBS, fasting
blood sugar; Hb A1c, glycosylated hemoglobin; Hb, hemoglobin; LDH, lactate dehydrogenase; TIBC: Total Iron-Binding Capacity; RBC, red blood cell; Total PSA, total
prostate specific antigen; WBC, white blood cell.
aHigher in comparison to the reference value.
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